243 related articles for article (PubMed ID: 33772327)
21. Bisphosphonates for the treatment of fibrous dysplasia of bone.
Chapurlat R; Legrand MA
Bone; 2021 Feb; 143():115784. PubMed ID: 33276154
[TBL] [Abstract][Full Text] [Related]
22. Regression of fibrous dysplasia in response to denosumab therapy: A report of two cases.
Meier ME; van der Bruggen W; van de Sande MAJ; Appelman-Dijkstra NM
Bone Rep; 2021 Jun; 14():101058. PubMed ID: 33912627
[TBL] [Abstract][Full Text] [Related]
23. Activation of RANK/RANKL/OPG Pathway Is Involved in the Pathophysiology of Fibrous Dysplasia and Associated With Disease Burden.
de Castro LF; Burke AB; Wang HD; Tsai J; Florenzano P; Pan KS; Bhattacharyya N; Boyce AM; Gafni RI; Molinolo AA; Robey PG; Collins MT
J Bone Miner Res; 2019 Feb; 34(2):290-294. PubMed ID: 30496606
[TBL] [Abstract][Full Text] [Related]
24. Fibrous dysplasia. Clinical review and therapeutic management.
Florez H; Peris P; Guañabens N
Med Clin (Barc); 2016 Dec; 147(12):547-553. PubMed ID: 27765282
[TBL] [Abstract][Full Text] [Related]
25. Outcome of Long-Term Bisphosphonate Therapy in McCune-Albright Syndrome and Polyostotic Fibrous Dysplasia.
Majoor BC; Appelman-Dijkstra NM; Fiocco M; van de Sande MA; Dijkstra PS; Hamdy NA
J Bone Miner Res; 2017 Feb; 32(2):264-276. PubMed ID: 27649526
[TBL] [Abstract][Full Text] [Related]
26. Treatment of fibrous dysplasia of bone with intravenous pamidronate: long-term effectiveness and evaluation of predictors of response to treatment.
Chapurlat RD; Hugueny P; Delmas PD; Meunier PJ
Bone; 2004 Jul; 35(1):235-42. PubMed ID: 15207763
[TBL] [Abstract][Full Text] [Related]
27. Effects of zoledronic acid therapy in fibrous dysplasia of bone: a single-center experience.
Valadares LP; de Araújo Ferreira BS; da Cunha BM; Moreira LA; Batista FGA; da Fonseca Hottz C; Magalhães GGR
Arch Endocrinol Metab; 2022 Apr; 66(2):247-255. PubMed ID: 35420267
[TBL] [Abstract][Full Text] [Related]
28. RANKL inhibition reduces lesional cellularity and Gα
de Castro LF; Whitlock JM; Michel Z; Pan K; Taylor J; Szymczuk V; Boyce B; Martin D; Kram V; Galisteo R; Melikov K; Chernomordik LV; Collins MT; Boyce AM
Bone Res; 2024 Feb; 12(1):10. PubMed ID: 38378678
[TBL] [Abstract][Full Text] [Related]
29. Long-term effects of intravenous pamidronate in fibrous dysplasia of bone.
Chapurlat RD; Delmas PD; Liens D; Meunier PJ
J Bone Miner Res; 1997 Oct; 12(10):1746-52. PubMed ID: 9333137
[TBL] [Abstract][Full Text] [Related]
30. Hypercalcemia after discontinuation of long-term denosumab treatment.
Koldkjær Sølling AS; Harsløf T; Kaal A; Rejnmark L; Langdahl B
Osteoporos Int; 2016 Jul; 27(7):2383-2386. PubMed ID: 27098536
[TBL] [Abstract][Full Text] [Related]
31. [Craniofacial fibrous dysplasia: about six cases].
Lame CA; Loum B; Diallo TB; Ndiaye CB; Diouf KMA; Fall A
Pan Afr Med J; 2020; 37():271. PubMed ID: 33598085
[TBL] [Abstract][Full Text] [Related]
32. Pamidronate treatment of bone fibrous dysplasia in nine children with McCune-Albright syndrome.
Lala R; Matarazzo P; Bertelloni S; Buzi F; Rigon F; de Sanctis C
Acta Paediatr; 2000 Feb; 89(2):188-93. PubMed ID: 10709889
[TBL] [Abstract][Full Text] [Related]
33. Denosumab: an Emerging Therapy in Pediatric Bone Disorders.
Boyce AM
Curr Osteoporos Rep; 2017 Aug; 15(4):283-292. PubMed ID: 28643220
[TBL] [Abstract][Full Text] [Related]
34. Prompt clinical and biochemical response to denosumab in a young adult patient with craniofacial fibrous dysplasia.
Eller-Vainicher C; Rossi DS; Guglielmi G; Beltramini GA; Cairoli E; Russillo A; Mantovani G; Spada A; Chiodini I
Clin Cases Miner Bone Metab; 2016; 13(3):253-256. PubMed ID: 28228794
[TBL] [Abstract][Full Text] [Related]
35. Malignant Sarcomatous Degeneration of Craniofacial Fibrous Dysplasia.
Hussaini AS; Swanson DD; Nguy PL; Pan KS; de Castro LF; Boyce AM; Collins MT; DeKlotz TR
J Craniofac Surg; 2022 Sep; 33(6):1787-1790. PubMed ID: 36054890
[TBL] [Abstract][Full Text] [Related]
36. Bisphosphonate therapy for fibrous dysplasia.
DiMeglio LA
Pediatr Endocrinol Rev; 2007 Aug; 4 Suppl 4():440-5. PubMed ID: 17982393
[TBL] [Abstract][Full Text] [Related]
37. [Aesthetic rehabilitation of a case of maxillary fibrous dysplasia in a child].
Pilavyan E; Wagner D; Clauss F; Strub M
Swiss Dent J; 2023 Mar; 133(3):165-170. PubMed ID: 36852500
[TBL] [Abstract][Full Text] [Related]
38. Elevated levels of circulating fibroblast growth factor 23 with hypercalcemia following discontinuation of denosumab.
Uchida T; Yamaguchi H; Kushima C; Yonekawa T; Nakazato M
Endocr J; 2020 Jan; 67(1):31-35. PubMed ID: 31527321
[TBL] [Abstract][Full Text] [Related]
39. Successful denosumab treatment for central giant cell granuloma in a 9-year-old child.
Mariz BALA; Migliorati CA; Alves FA; Penteado FM; Carvalho NP; Santos-Silva AR; Rocha AC
Spec Care Dentist; 2021 Jul; 41(4):519-525. PubMed ID: 33760257
[TBL] [Abstract][Full Text] [Related]
40. EFFICACY AND SAFETY OF BISPHOSPHONATE THERAPY IN MCCUNE-ALBRIGHT SYNDROME-RELATED POLYOSTOTIC FIBROUS DYSPLASIA: A SINGLE-CENTER EXPERIENCE.
Wang Y; Wang O; Jiang Y; Li M; Xia W; Meng X; Xing X
Endocr Pract; 2019 Jan; 25(1):23-30. PubMed ID: 30383490
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
